JP2011518113A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518113A5 JP2011518113A5 JP2010542631A JP2010542631A JP2011518113A5 JP 2011518113 A5 JP2011518113 A5 JP 2011518113A5 JP 2010542631 A JP2010542631 A JP 2010542631A JP 2010542631 A JP2010542631 A JP 2010542631A JP 2011518113 A5 JP2011518113 A5 JP 2011518113A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- nucleic acid
- acid molecule
- solid phase
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 239000007790 solid phase Substances 0.000 claims description 16
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229920000592 inorganic polymer Polymers 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims 15
- 102000039446 nucleic acids Human genes 0.000 claims 15
- 150000007523 nucleic acids Chemical class 0.000 claims 15
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 108060003951 Immunoglobulin Proteins 0.000 claims 5
- 102000018358 immunoglobulin Human genes 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 2
- 102000017910 Adrenergic receptor Human genes 0.000 claims 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 239000002122 magnetic nanoparticle Substances 0.000 claims 2
- 210000004498 neuroglial cell Anatomy 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 101710137556 L-2-aminoadipate reductase Proteins 0.000 claims 1
- 101710131054 L-2-aminoadipate reductase large subunit Proteins 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 150000001540 azides Chemical group 0.000 claims 1
- 238000004166 bioassay Methods 0.000 claims 1
- 239000011616 biotin Chemical group 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 239000003547 immunosorbent Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 239000012071 phase Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08100510.0 | 2008-01-15 | ||
| EP08100510A EP2080519A1 (en) | 2008-01-15 | 2008-01-15 | Peptides having binding affinity to an antibody which recognizes an epitope on an alpha1 loop 2 or beta 2 loop 1 of an adrenoreceptor |
| PCT/EP2009/050446 WO2009090227A2 (en) | 2008-01-15 | 2009-01-15 | PEPTIDES HAVING BINDING AFFINITY TO AN ANTIBODY WHICH RECOGNIZES AN EPITOPE ON AN α1 LOOP 2 OR β2 LOOP 1 OF AN ADRENORECEPTOR |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011518113A JP2011518113A (ja) | 2011-06-23 |
| JP2011518113A5 true JP2011518113A5 (enExample) | 2014-02-20 |
| JP5671347B2 JP5671347B2 (ja) | 2015-02-18 |
Family
ID=39402559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010542631A Expired - Fee Related JP5671347B2 (ja) | 2008-01-15 | 2009-01-15 | アドレナリン受容体のα１ループ２またはβ２ループ１上のエピトープを認識する抗体に対して結合親和性を有するペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8455442B2 (enExample) |
| EP (2) | EP2080519A1 (enExample) |
| JP (1) | JP5671347B2 (enExample) |
| ES (1) | ES2639573T3 (enExample) |
| WO (1) | WO2009090227A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2497828A1 (en) | 2011-03-07 | 2012-09-12 | Charité - Universitätsmedizin Berlin | Use of aptamers in therapy and/or diagnosis of autoimmune diseases |
| US20140199318A1 (en) | 2011-08-12 | 2014-07-17 | Max-Del-Bruck-Centrum Fur Molekulare Medizin | Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia |
| KR20150032265A (ko) * | 2012-06-26 | 2015-03-25 | 에프. 호프만-라 로슈 아게 | 세포 침투성 펩티드 및 세포 침투성 펩티드의 식별 방법 |
| JP2017515799A (ja) * | 2014-04-03 | 2017-06-15 | オウ テルヴィスリク ピーマ バイオテウノロジーテ アレンダスケスクス | コレステロール低下剤およびクロストリジウム・ディフィシレに対する抗微生物剤としてのラクトバチルス・プランタルムＩｎｄｕｃｉａ株ＤＳＭ２１３７９ |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU677968B2 (en) * | 1992-09-25 | 1997-05-15 | H. Lundbeck A/S | DNA encoding human alpha 1 adrenergic receptors and uses thereof |
| JP2003514772A (ja) * | 1999-09-21 | 2003-04-22 | アフィーナ イミュンテヒニク ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｃｍを引き起こす自己抗体に対するペプチド |
| WO2002038592A2 (de) * | 2000-11-08 | 2002-05-16 | Affina Immuntechnik Gmbh | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen |
| US6451547B1 (en) * | 2001-04-25 | 2002-09-17 | Syn X Pharma | Process for differential diagnosis of Alzheimer's dementia and device therefor |
| US20020172676A1 (en) * | 2001-05-16 | 2002-11-21 | George Jackowski | Method of treatment of alzheimer's disease and device therefor |
| WO2004051280A2 (de) * | 2002-11-29 | 2004-06-17 | Max-Delbrück-Centrum für Molekulare Medizin | Bestimmung agonistischer autoantikörper |
| JP2008537961A (ja) * | 2005-04-15 | 2008-10-02 | ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ | Ｇｐｃｒモジュレーター |
| EP1832600A1 (en) * | 2006-03-09 | 2007-09-12 | Max-Delbrück-Centrum Für Molekulare Medizin | Peptides against autoantibodies associated with glaucoma and use of these peptides |
| WO2008151847A1 (en) | 2007-06-13 | 2008-12-18 | Max-Delbrück-Centrum für Molekulare Medizin | Autoantibody binding peptides and their use for the treatment of vascular diseases |
| WO2009132283A2 (en) * | 2008-04-24 | 2009-10-29 | University Of Miami | Method for treating autoimmune disorders |
| US8216786B2 (en) * | 2008-07-09 | 2012-07-10 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
-
2008
- 2008-01-15 EP EP08100510A patent/EP2080519A1/en not_active Ceased
-
2009
- 2009-01-15 US US12/735,416 patent/US8455442B2/en not_active Expired - Fee Related
- 2009-01-15 WO PCT/EP2009/050446 patent/WO2009090227A2/en not_active Ceased
- 2009-01-15 EP EP09702027.5A patent/EP2244718B1/en active Active
- 2009-01-15 JP JP2010542631A patent/JP5671347B2/ja not_active Expired - Fee Related
- 2009-01-15 ES ES09702027.5T patent/ES2639573T3/es active Active
-
2013
- 2013-04-26 US US13/871,239 patent/US9574017B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chorev | The partial retro–inverso modification: a road traveled together | |
| JP6997160B2 (ja) | 血液、血液生産物及び器官を処置する方法 | |
| CN118546242A (zh) | 突变的免疫球蛋白-结合多肽 | |
| JP2010254694A5 (enExample) | ||
| JP2014221801A5 (enExample) | ||
| JP2012503026A5 (enExample) | ||
| JP2015134758A5 (enExample) | ||
| Wang et al. | Revisiting oxytocin through the medium of isonitriles | |
| JP2010514779A5 (enExample) | ||
| CN105658228B (zh) | 结合人类补体c5的稳定多肽 | |
| JP2011518113A5 (enExample) | ||
| Yang et al. | Preparation of an epitope-imprinted polymer with antibody-like selectivity for beta2-microglobulin and application in serum sample analysis with a facile method of on-line solid-phase extraction coupling with high performance liquid chromatography | |
| CN112789295B (zh) | 包含IgG结合肽的固相担载体及IgG的分离方法 | |
| WO2012096893A2 (en) | Antigen surrogates in autoimmune disease | |
| Kruljec et al. | Development and characterization of peptide ligands of immunoglobulin G Fc region | |
| EP2614371B1 (en) | Method for labeling of compounds | |
| BRPI0712496A2 (pt) | peptìdeo isolado, composição compreendendo o referido peptìdeo, ácido nucléico isolado e métodos de purificar uma proteìna na superfamìlia do fator beta de transformação do crescimento (tgf-?) e de estabilizar uma solução contendo uma proteìna na superfamìlia tgf-b. | |
| CN105745220A (zh) | 结合β淀粉状蛋白的环状肽及其用途 | |
| CN105745219A (zh) | 结合β淀粉状蛋白的肽及其用于治疗和诊断阿尔茨海默痴呆症的用途 | |
| JP2023545375A (ja) | Ａａｖ８親和剤 | |
| Lee et al. | Synthesis of a high affinity complementary peptide–polymer nanoparticle (NP) pair using phage display | |
| US11104705B2 (en) | Methods for removing bacterial toxins from a biological fluid | |
| JP2024508587A (ja) | Ａａｖ２親和剤 | |
| WO2010069570A2 (en) | Peptides against autoantibodies associated with crps and use of these peptides | |
| JP2008509659A5 (enExample) |